- Home
- CRNX
as 11-15-2024 4:00pm EST
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 5.3B | IPO Year: | 2018 |
| Target Price: | $73.70 | AVG Volume (30 days): | 655.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $28.50 - $62.53 | Next Earning Date: | 11-12-2024 |
| Revenue: | $1,038,999 | Revenue Growth: | -78.00% |
| Revenue Growth (this year): | -49.31% | Revenue Growth (next year): | 494.25% |
Stock Insider Trading Activity of Crinetics Pharmaceuticals Inc. (CRNX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Oct 3 '24 | Sell | $54.63 | 14,375 | $785,306.25 | 28,507 | |
| Wilson Marc | CRNX | CFO | Sep 26 '24 | Sell | $51.11 | 25,000 | $1,277,750.00 | 111,092 | |
| Betz Stephen F. | CRNX | Chief Scientific Officer | Sep 10 '24 | Sell | $51.50 | 1,035 | $53,302.50 | 68,576 | |
| Betz Stephen F. | CRNX | Chief Scientific Officer | Aug 26 '24 | Sell | $53.19 | 3,000 | $159,570.00 | 68,576 |
Latest Crinetics Pharmaceuticals Inc. News
CRNX Breaking Stock News: Dive into CRNX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
GlobeNewswire
3 days ago
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
Simply Wall St.
3 days ago
Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023)
GuruFocus.com
4 days ago
Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
MT Newswires
5 days ago
Crinetics Pharmaceuticals Q3 Net Loss Narrows
GlobeNewswire
5 days ago
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
GlobeNewswire
5 days ago
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
6 days ago
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare CRNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRNX Crinetics Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.